This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks With Big Insider Buying

Vivus

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One biotechnology and drugs player that insiders are loading up on here is Vivus (VVUS), which is engaged in the development and commercialization of therapeutic drugs for underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes, and men's sexual health. Insiders are buying this stock into strength, since shares are up a whopping 134% so far in 2012.

Vivus has a market cap of $2.31 billion and an enterprise value of $2.02 billion. This stock trades at a premium valuation, with a forward price-to-earnings of 57.62. Its estimated growth rate for this year is -75%, and for next year it's pegged at 140.8%. This is a cash-rich company, since the total cash position on its balance sheet is $310.39 million, and its total debt is zero.

A director just bought 20,000 shares, or about $434,000 worth of stock, at $21.50 per share.

>>5 Biotech Stocks Under $10 Blasting Higher

From a technical perspective, VVUS is currently trading below both its 50-day moving average and above its 200-day moving average, which is neutral trendwise. This stock recently sold off after it printed its 52-week high of $31.21 a share to its August low of $19.75 a share. Since hitting that low, shares of VVUS have been trading range bound between $19.75 on the downside and $23.52 on the upside. A move outside of that range will likely setup the next major trend for VVUS.

If you're bullish on VVUS, then I would look for long-biased trades once this stock triggers a breakout above some near-term overhead resistance at $23.52 to its 50-day moving average of $25.09 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 4.9 million shares. If that breakout triggers soon, then VVUS could setup to re-test its 52-week high of $31.21.

On the flipside, I would avoid VVUS or look for short-biased trades if this stock fails to trigger that breakout soon and then drops back below some major support levels at $21.31 to $19.75 a share, and then below its 200-day moving average of $18.57 a share with heavy volume. Any high-volume move below those levels will set this stock up for a decent fall.

2 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,234.72 +77.87 0.45%
S&P 500 2,010.44 +8.87 0.44%
NASDAQ 4,588.0670 +25.8780 0.57%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs